• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    3 Penny Stocks With Market Caps Over $5M To Watch

    Simply Wall St·10/03/2025 11:04:56
    Listen to the news

    As U.S. markets continue to rise, with major indices setting fresh records despite concerns over a government shutdown, investors are exploring opportunities beyond the traditional blue-chip stocks. Penny stocks, often seen as relics of past speculative trading days, still hold potential when backed by strong financials and solid business models. These smaller or newer companies can offer unique growth prospects and hidden value for those willing to explore beyond the well-trodden paths of larger corporations.

    Top 10 Penny Stocks In The United States

    Name Share Price Market Cap Rewards & Risks
    Dingdong (Cayman) (DDL) $2.06 $441.47M ✅ 4 ⚠️ 0 View Analysis >
    Waterdrop (WDH) $1.89 $683.54M ✅ 4 ⚠️ 0 View Analysis >
    Performance Shipping (PSHG) $1.89 $24.24M ✅ 4 ⚠️ 2 View Analysis >
    CI&T (CINT) $4.89 $654.03M ✅ 5 ⚠️ 0 View Analysis >
    Golden Growers Cooperative (GGRO.U) $5.00 $77.45M ✅ 2 ⚠️ 5 View Analysis >
    Table Trac (TBTC) $4.59 $21.81M ✅ 2 ⚠️ 2 View Analysis >
    BAB (BABB) $1.00 $6.9M ✅ 2 ⚠️ 3 View Analysis >
    Lifetime Brands (LCUT) $3.83 $85.87M ✅ 3 ⚠️ 2 View Analysis >
    Universal Safety Products (UUU) $4.60 $11.06M ✅ 2 ⚠️ 3 View Analysis >
    Resources Connection (RGP) $4.88 $168.52M ✅ 3 ⚠️ 1 View Analysis >

    Click here to see the full list of 365 stocks from our US Penny Stocks screener.

    Here we highlight a subset of our preferred stocks from the screener.

    Alto Neuroscience (ANRO)

    Simply Wall St Financial Health Rating: ★★★★★☆

    Overview: Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company based in the United States with a market cap of $110.20 million.

    Operations: Currently, there are no reported revenue segments for this clinical-stage biopharmaceutical company.

    Market Cap: $110.2M

    Alto Neuroscience, Inc., with a market cap of US$110.20 million, is a pre-revenue clinical-stage biopharmaceutical company focused on innovative neuropsychiatric treatments. Recent positive results from an EEG biomarker study in schizophrenia highlight its potential in precision psychiatry, though the company remains unprofitable with increasing losses reported. Despite being dropped from the S&P Global BMI Index and facing a class action lawsuit related to its IPO, Alto maintains strong short-term liquidity with cash assets exceeding liabilities significantly. The management team is experienced but relatively new; however, earnings are forecasted to decline over the next three years.

    ANRO Financial Position Analysis as at Oct 2025
    ANRO Financial Position Analysis as at Oct 2025

    Chegg (CHGG)

    Simply Wall St Financial Health Rating: ★★★★★☆

    Overview: Chegg, Inc. offers personalized learning support aimed at enhancing academic, life, and job skills for students both in the United States and internationally, with a market cap of approximately $175.49 million.

    Operations: The company generates revenue primarily through its Educational Services segment, specifically in Education & Training Services, amounting to $506.58 million.

    Market Cap: $175.49M

    Chegg, Inc., with a market cap of US$175.49 million, faces challenges as it remains unprofitable with increasing losses over the past five years. Despite this, Chegg has reduced its debt-to-equity ratio significantly and maintains a cash runway exceeding three years due to positive free cash flow. Recent earnings guidance projects third-quarter revenue between US$75 million and US$77 million. Although sales have declined compared to the previous year, net losses have decreased substantially from prior periods. The company completed a significant share buyback program but has experienced high share price volatility recently.

    CHGG Debt to Equity History and Analysis as at Oct 2025
    CHGG Debt to Equity History and Analysis as at Oct 2025

    Lithium (LTUM)

    Simply Wall St Financial Health Rating: ★★★★★★

    Overview: Lithium Corporation is an exploration stage mining company focused on identifying, acquiring, and exploring metals and minerals in Nevada and British Columbia, with a market cap of $5.06 million.

    Operations: Currently, there are no reported revenue segments for the company.

    Market Cap: $5.06M

    Lithium Corporation, with a market cap of US$5.06 million, is pre-revenue and faces challenges as it remains unprofitable. Despite this, the company has no debt and maintains sufficient cash runway for over three years even if free cash flow declines at historical rates. Recent earnings results show reduced net losses compared to the previous year. The board of directors is experienced with an average tenure of 12.8 years, but the stock exhibits high volatility with weekly fluctuations increasing significantly over the past year from 132% to 259%. Short-term assets exceed liabilities by US$0.5 million, providing some financial stability amidst its exploration activities in Nevada and British Columbia.

    LTUM Financial Position Analysis as at Oct 2025
    LTUM Financial Position Analysis as at Oct 2025

    Summing It All Up

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.